

Table SV. Consumption volume of topical and emollient therapy

Consumption volume	Baseline		After 3 months		After 6 months		Differential group difference after the intervention (T3 +T4), <i>p</i> -value
	Mean g (SD)	Median (min–max)	Mean g (SD)	Median (min–max)	Mean (SD)	Median (min–max)	
	MI (<i>n</i> = 86)	TAU (<i>n</i> = 83)	MI (<i>n</i> = 72)	TAU (<i>n</i> = 63)	MI (<i>n</i> = 65)	TAU (<i>n</i> = 60)	
Total amount of used HC and prescription anti-PSO medicine (all topical treatment)	78 (159) 167.50 (0–1,660.00)	70 (105) 100.00 (0–1,240.00)	67 (108) 120.00 (0–2,120.00)	92 (107) 130.00 (0–1,660.00)	92 (157) 120.00 (0–1,200.00)	95 (164) 125.00 (0–1,225.00)	<i>Z</i> = –0.32, <i>p</i> = 0.75 ^a
Total amount of used OTC body lotion and emollients	836 (1,028) 500.00 (0–5,350.00)	812 (1,139) 500.0 (0–7,750.00)	1,169 (977) 1,000.00 (0–4,960)	1,032 (966) 925.00 (0–5,500.00)	1,235 (1,207) 1,000 (0–6,175.00)	971 (1,522) 600.00 (0–10,380.00)	<i>Z</i> = –1.44, <i>p</i> = 0.15 ^a

T3: 3 months after CHT (after the MI intervention); T4: 6 months after CHT. Cost group 2: use of self-care products (hydrocortisone (HK), systemic psoriasis therapy, topical treatment, emollients and body lotion) at each follow-up, by treatment group (mean, SD) or (mean, SD and median (min–max)).
^aMann–Whitney U test of medians.

PSO: psoriasis; HC: healthy controls; TAU: treatment-as-usual; CHT: climate heliotherapy; SD: standard deviation; MI: motivational interviewing; OTC: over-the-counter.